Literature DB >> 25249540

Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment.

Atthaphorn Trakarnsanga1, Mithat Gönen1, Jinru Shia1, Garrett M Nash1, Larissa K Temple1, José G Guillem1, Philip B Paty1, Karyn A Goodman1, Abraham Wu1, Marc Gollub1, Neil Segal1, Leonard Saltz1, Julio Garcia-Aguilar1, Martin R Weiser2.   

Abstract

BACKGROUND: Tumor regression grade (TRG) is a measure of histopathological response of rectal cancer to neoadjuvant chemoradiation and is associated with outcomes. Several TRG systems are used: Mandard (5,3-tier), Dowrak/Rödel (5,3-tier), Memorial Sloan Kettering Cancer Center (MSKCC), and American Joint Committee on Cancer (AJCC) Cancer Staging. A single measure of rectal cancer response would assist in comparing results across institutions, and in designing future rectal cancer studies. In this study, the predictive accuracies of the various published classification schemes are compared.
METHODS: Review of a prospective database identified 563 patients with locally advanced rectal cancer (T3/4 and/or N1) treated between 1998 and 2007 with long-course chemoradiation and total mesorectal excision. TRG was determined by measuring proportion of tumor mass replaced by fibrosis. Patients were classified into TRG schemes, which were compared by analyzing association with recurrence and survival using concordance index. Probabilities of recurrence-free survival were estimated using the Kaplan-Meier method. All statistical tests were two-sided.
RESULTS: All TRG systems were predictive of recurrence. Concordance indices of the three-tier Mandard, three-tier Dowrak/Rödel, three-tier MSKCC, and four-tier AJCC systems were: 0.665, 0.653, 0.683, and 0.694, respectively (higher number = better prediction). The AJCC system more accurately predicted recurrence than the three-tier Mandard (P = .002) or Dowrak/Rödel (P = .006) and had a higher concordance index than MSKCC, although this did not reach statistical significance (P = .068).
CONCLUSION: When classifying rectal cancer response to chemoradiation, the AJCC Staging Manual (7(th) edition) system is most accurate and should be adopted as the standard.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 25249540      PMCID: PMC4271114          DOI: 10.1093/jnci/dju248

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

1.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

2.  Complete pathologic response after preoperative rectal cancer chemoradiotherapy.

Authors:  Anthony Ciccocioppo; Jacqueline H Stephens; Peter J Hewett; Nicholas A Rieger
Journal:  ANZ J Surg       Date:  2009-06       Impact factor: 1.872

3.  Reclassification calculations for persons with incomplete follow-up.

Authors:  Ewout W Steyerberg; Michael J Pencina
Journal:  Ann Intern Med       Date:  2010-02-02       Impact factor: 25.391

4.  Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer.

Authors:  A S Dhadda; P Dickinson; A M Zaitoun; N Gandhi; E M Bessell
Journal:  Eur J Cancer       Date:  2011-01-08       Impact factor: 9.162

5.  Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).

Authors:  Seung-Gu Yeo; Dae Yong Kim; Tae Hyun Kim; Hee Jin Chang; Jae Hwan Oh; Won Park; Doo Ho Choi; Heerim Nam; Jun-Sang Kim; Moon-June Cho; Jong Hoon Kim; Jin-Hong Park; Min Kyu Kang; Woong Sub Koom; Jae-Sung Kim; Taek-Keun Nam; Eui Kyu Chie; Jung Soo Kim; Kyung-Ja Lee
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

6.  Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy.

Authors:  Lorena Losi; Gabriele Luppi; Margherita Gavioli; Francesco Iachetta; Federica Bertolini; Roberto D'Amico; Gordana Jovic; Filippo Bertoni; Anna Maria Falchi; Pier Franco Conte
Journal:  Int J Colorectal Dis       Date:  2005-11-30       Impact factor: 2.571

7.  Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.

Authors:  J Suárez; R Vera; E Balén; M Gómez; F Arias; J M Lera; J Herrera; C Zazpe
Journal:  Colorectal Dis       Date:  2007-12-07       Impact factor: 3.788

8.  Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.

Authors:  Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard B Saltz; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; Martin R Weiser
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

9.  A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.

Authors:  D Beddy; J M P Hyland; D C Winter; C Lim; A White; M Moriarty; J Armstrong; D Fennelly; D Gibbons; K Sheahan
Journal:  Ann Surg Oncol       Date:  2008-10-10       Impact factor: 5.344

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

View more
  62 in total

1.  College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Authors:  Hai-Yang Chen; Li-Li Feng; Ming Li; Huai-Qiang Ju; Yi Ding; Mei Lan; Shu-Mei Song; Wei-Dong Han; Li Yu; Ming-Biao Wei; Xiao-Lin Pang; Fang He; Shuai Liu; Jian Zheng; Yan Ma; Chu-Yang Lin; Ping Lan; Mei-Jin Huang; Yi-Feng Zou; Zu-Li Yang; Ting Wang; Jin-Yi Lang; Guy R Orangio; Vitaliy Poylin; Jaffer A Ajani; Wei-Hu Wang; Xiang-Bo Wan
Journal:  Oncologist       Date:  2021-02-22

Review 2.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

3.  CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.

Authors:  Sylvain Ferrandon; Jennifer DeVecchio; Leonardo Duraes; Hanumant Chouhan; Georgios Karagkounis; Jacqueline Davenport; Matthew Orloff; David Liska; Matthew F Kalady
Journal:  Cancer Res       Date:  2019-11-08       Impact factor: 12.701

4.  Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes.

Authors:  C S D Roxburgh; P Strombom; P Lynn; A Cercek; M Gonen; J J Smith; L K F Temple; G M Nash; J G Guillem; P B Paty; J Shia; E Vakiani; R Yaeger; Z K Stadler; N H Segal; D Reidy; A Varghese; A J Wu; C H Crane; M J Gollub; L B Saltz; J Garcia-Aguilar; M R Weiser
Journal:  Colorectal Dis       Date:  2019-07-01       Impact factor: 3.788

5.  Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.

Authors:  Matthew Alderdice; Philip D Dunne; Aidan J Cole; Paul G O'Reilly; Darragh G McArt; Vicky Bingham; Marc-Aurel Fuchs; Stephen McQuaid; Maurice B Loughrey; Graeme I Murray; Leslie M Samuel; Mark Lawler; Richard H Wilson; Manuel Salto-Tellez; Vicky M Coyle
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 6.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

7.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

8.  Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.

Authors:  Cynthia Gail Leichman; Shannon L McDonough; Stephen R Smalley; Kevin G Billingsley; Heinz-Josef Lenz; Matthew A Beldner; Aram F Hezel; Mario R Velasco; Katherine A Guthrie; Charles D Blanke; Howard S Hochster
Journal:  Clin Colorectal Cancer       Date:  2017-10-24       Impact factor: 4.481

9.  Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.

Authors:  Vincenzo Formica; Michaela Benassi; Giovanna Del Vecchio Blanco; Elena Doldo; Laura Martano; Ilaria Portarena; Antonella Nardecchia; Jessica Lucchetti; Cristina Morelli; Emilia Giudice; Piero Rossi; Alessandro Anselmo; Pierpaolo Sileri; Giuseppe Sica; Augusto Orlandi; Riccardo Santoni; Mario Roselli
Journal:  Med Oncol       Date:  2018-05-02       Impact factor: 3.064

10.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.